BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms ...
Hot flashes are one of the most frequent and disruptive vasomotor symptoms associated with the menopausal transition. They involve a sudden wave of heat, usually beginning in the face, neck, or chest, ...
News-Medical.Net on MSN
Midlife insulin levels influence timing and duration of menopausal vasomotor symptoms
A woman's insulin levels in midlife are linked to the timing and duration of menopausal hot flashes, night sweats and cold ...
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause "Today's approval of fezolinetant is a significant and, I believe, long ...
Elinzanetant improves sleep disturbances independent of improvements in vasomotor symptoms, according to data presented at The Menopause Society 2025 Annual Meeting. Elinzanetant is a nonhormonal drug ...
Women receiving daily oral estetrol reported significantly fewer hot flashes and night sweats than those receiving placebo without any notable effects on blood pressure, according to research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results